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ABSTRACT
Proteasomal degradation of topoisomerase I (topoI) is one of the most 
remarkable cellular phenomena observed in response to camptothecin (CPT). 
Importantly, the rate of topoI degradation is linked to CPT resistance. Formation of 
the topoI-DNA-CPT cleavable complex inhibits DNA re-ligation resulting in DNA-double 
strand break (DSB). The degradation of topoI marks the first step in the ubiquitin 
proteasome pathway (UPP) dependent DNA damage response (DDR). Here, we show 
that the Ku70/Ku80 heterodimer binds with topoI, and that the DNA-dependent 
protein kinase (DNA-PKcs) phosphorylates topoI on serine 10 (topoI-pS10), which 
is subsequently ubiquitinated by BRCA1. A higher basal level of topoI-pS10 ensures 
rapid topoI degradation leading to CPT resistance. Importantly, PTEN regulates DNA-
PKcs kinase activity in this pathway and PTEN deletion ensures DNA-PKcs dependent 
higher topoI-pS10, rapid topoI degradation and CPT resistance.
INTRODUCTION
Human DNA-topoisomerase I (topoI) reduces 
DNA supercoiling generated during transcription and 
replication. The enzyme also plays important roles in 
chromatin assembly, recombination, and chromosome 
segregation [1, 2]. TopoI was identified as a specific target 
for the anticancer drug camptothecin (CPT) [3]. Two CPT 
analogues, topotecan and irinotecan are used extensively 
to treat colon, ovarian, pancreatic, breast and small cell 
lung cancer. Several 3rd generation nano-encapsulated 
or non-CPT topoI inhibitors are in various phases of 
clinical development. As a group, CPTs represent one 
of the most potent classes of anticancer drugs. However, 
only 13-32% of cancer patients respond to CPTs and 
mechanisms of resistance are not well understood [4]. 
Three proposed mechanisms of CPT resistance are: i) 
lack of drug accumulation due to MDR/ABC transporter, 
ii) topoI gene mutation, and iii) ubiquitin proteasomal 
pathway (UPP) mediated degradation of topoI in response 
to CPT [5]. However, recent studies have shown that 
CPTs are not MDR substrates, topoI mutations are 
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rare, and they do not account for drug resistance in the 
patient population [6-10], leaving degradation of topoI 
as a major potential mechanism of CPT resistance. 
Other suggested mechanisms for resistance, including 
regulation of DNA damage response (DDR) pathways, 
have not been validated, and DNA repair pathways 
in tumor cells are often defective. Moreover, reports 
on siRNA library screening and CPT response did not 
identify a specific gene responsible for resistance [11, 12]. 
It was also observed that topoI protein levels, mRNA or 
number of cleavable complexes had no correlation with 
CPT response [13]. One of the most distinct cellular 
responses to CPT is the degradation of topoI by the UPP. 
It was first observed in peripheral leukocytes of patients 
receiving 9-amino camptothecin [14], and subsequently 
in multiple cancer cell lines [15]. Additionally, other 
studies have shown that topoI is degraded by the UPP 
[16]. These findings that topoI degrades differentially 
and that the rate of degradation is linked to CPT response 
was an important observation [17]. This study clearly 
demonstrated that CPT-induced topoI degradation is 
not a universal phenomenon and cells representing the 
same tumor type degrade topoI deferentially. However, 
the molecular determinants of CPT-induced topoI 
degradation have not yet been identified. Phosphorylation 
is another post-translational modification (PTM) that 
regulates topoI enzyme activity. TopoI was identified 
as a phosphoprotein and de-phosphorylation of topoI 
completely eliminates its enzymatic activity [18, 19]. 
Taken together, phosphorylation and ubiquitination are 
two well-documented PTMs identified as key regulators of 
topoI functions. Cross talk between phosphorylation and 
ubiquitination is well documented [20], and is pertinent to 
define the molecular fabric of both pathways in order to 
identify the determinants for CPT resistance. 
RESULTS
Isolation of topoI interacting protein complex
We used an improvised GST-pull down assay to 
isolate topoI-associated protein complexes [21, 22]. GST-
topoI interacting proteins were eluted in buffer containing 
350 or 500 mM NaCl and analyzed by SDS-PAGE and 
silver staining (Figure 1A). The proteins specifically 
associated with topoI, were in-gel trypsin digested and 
identified by mass spectrometry. More than nine topoI-
interacting proteins were identified including Ku70/Ku80 
heterodimer and the BRCT domain of BRCA1. Since the 
BRCA1 is a 220 KDa protein and the isolated fragment in 
our assays migrated to 65 kDa, we interpreted the faster 
migrating band to be a proteolytic fragment of BRCA1. 
As control, the assays were normalized by GST pull down 
(Figure 1A).
TopoI associates with Ku70-Ku80-DNA-PKcs 
complex in cells
Human topoI, a type 1B enzyme, can relax both 
negative and positive DNA super coiling by cutting and re-
ligating the DNA. However, in the presence of CPTs, the 
re-ligation step is stalled, and the progressing replication 
fork during S phase converts the nicked DNA into a 
DNA-double strand break (DSB) [1, 2]. The Ku70/Ku80 
heterodimer recognizes DNA-DSB and targets the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) 
to the site of strand break to initiate DSB repair by non-
homologous end joining (NHEJ) [23]. Thus, our findings 
provided a potential functional basis for the putative 
association between topoI and the Ku70/80 heterodimer. 
To further understand the association between topoI and 
the Ku70/Ku80 heterodimer, GST and GST-topoI were 
separately bound to sepharose beads, incubated with 
HeLa cell lysates and adsorbates were immunoblotted 
with antibodies to Ku80, Ku70 or DNA-PKcs. The results 
demonstrate that in contrast to GST, Ku80 (Figure 1B left 
panel), Ku70 (Figure 1B middle panel) and DNA-PKcs 
(Figure 1B right panel) proteins were identified in the 
GST-topoI adsorbates. To rule out the possibility of DNA 
strand-mediated association, we have added ethidium 
bromide in the binding and wash buffer. To validate 
further these associations, immunoblot analysis of topoI 
immunoprecipitates demonstrated co-precipitation of a 
Ku70-Ku80-DNA-PKcs complex with topoI (Figure 1C, 
left panel). Similar results were obtained in the reciprocal 
experiment in which anti-topoI immunoprecipitates were 
analyzed by immunoblotting with anti-Ku70 (Figure 1C, 
middle panel) and anti-Ku80 (Figure 1C, right panel). 
Taken together, these findings strongly indicated that topoI 
is in the complex of Ku70-Ku80-DNA-PKcs.
TopoI Serine 10 is phosphorylated by DNA-PKcs
In the response to DNA-DSBs, DNA-PKcs 
forms a complex with Ku70/Ku80 heterodimer and the 
complex is referred to as DNA-PK. To understand the 
cellular function of topoI-DNA-PK association, we first 
asked if topoI is phosphorylated by DNA-PK. GST-
topoI was incubated with purified DNA-PK and the 
kinase reaction products were analyzed by SDS-PAGE 
and autoradiography. The results demonstrated that 
DNA-PK phosphorylates topoI in vitro (Figure 1D). To 
identify the site of phosphorylation, topoI protein was 
digested and analyzed by mass spectrometry. Analysis 
of immobilized metal affinity chromatography (IMAC) 
enriched phosphopeptide resulted in the identification of 
[GSD]MSGDHLHNDpSQIEADFR peptide. This trypsin 
digested GST-topoI peptide contains three amino acids 
[GSD] from the GST protein, while the remaining 17 
amino acids were from the N-terminus of topoI. The y and 
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b ion series confirmed the sequence of peptides, as well as 
the phosphorylation of Serine 10 of topoI (Figure 1E). No 
phosphorylation was observed when a mutant (S10A) 
topoI was incubated with the purified DNA-PK (Figure 1F 
and Supplementary Figure S1A). These findings indicated 
that topoI-S10 is the only site that is phosphorylated by 
DNA-PK in vitro. As one measure of the significance of 
topoI S10 phosphorylation, the conservation of aa 1-20 
was determined by BLAST analysis. Furthermore, in this 
context, the sequence homology surrounding topoI S10 
and the SQ motif (the consensus motif for DNA-PKcs 
phosphorylation) is highly conserved (Figure 1G). 
CPT-induced topoI degradation requires DNA-
PKcs dependent phosphorylation of topoI-S10
To determine the role of topoI-S10 phosphorylation 
on topoI regulation, we assessed topoI protein and 
mRNA level as well as its activity in ScSV3-MEF (DNA-
PKcs-/-) cells and kinase reconstituted ScH8-MEF (DNA-
PKcs+/+) cells [24]. Immunoblot analysis of ScSV3 and 
ScH8 cells demonstrated deletion of DNA-PKcs protein 
in ScSV3 cells as expected (Figure 2A). We then asked 
if there is any functional difference in topoI activity in 
Figure 1: DNA-PK interacts with topoI and DNA-PKcs phosphorylates topoI at S10. A. Improvised GST and GST-topoI 
pull downs were performed with HeLa nuclear extract and proteins associated with GST and GST-topoI were analyzed by SDS-PAGE and 
silver staining. B. GST and GST-topoI pull down experiments with HeLa nuclear extract were performed in small scale and adsorbates 
were immunoblotted with the indicated antibodies. C. HeLa cell lysates were subjected to immunoprecipitation with IgG, anti-Ku70, 
anti-Ku80, and anti-DNA-PKcs. Hela lysates were also subjected to immunoprecipitation with anti-topoI and immunoprecipitates were 
immunoblotted with anti-Ku70 (middle panel) and anti-Ku80 (right panel). D. DNA-PKcs kinase reactions were performed with GST-topoI 
and without topoI, and the reaction products were analyzed by SDS-PAGE, coomassie stain and autoradiography. E. DNA-PKcs kinase 
reactions were performed with GST-topoI and the reaction products were analyzed by SDS-PAGE and coomassie staining. GST-topoI was 
excised, trypsin digested, and analyzed by ESI-MS/MS. The MS/MS spectrum of IMAC enriched phosphopeptide shows fragment ions 
with topoI-S10 phosphorylation. F. DNA-PKcs kinase reactions were performed with GST-topoI-WT and GST-topoI-S10A mutant, and 
the reaction products were analyzed by SDS-PAGE, coomassie stain and autoradiography. G. Sequence alignment of the topoI N-terminal 
region.
Oncotarget43736www.impactjournals.com/oncotarget
these cell lines. The results demonstrate no difference in 
topoI proteins (Figure 2B), mRNA or enzyme activity 
(Figure 2C and 2D). Importantly, the cellular response 
to CPT was remarkably different in these cell lines. Our 
results demonstrated that in response to CPT, the topoI 
protein was rapidly degraded in DNA-PKcs proficient 
ScH8 cells, while no or minimal topoI degradation was 
observed in DNA-PKcs deficient ScSV3 cells (Figure 
2E and 2F). To substantiate the evidence, we next used 
a inhibitor of DNA-PKcs (NU7026) and determined 
that topoI is not degraded in response to CPT in the 
presence of NU7026 (Figure 2G and 2H). The rate of 
topoI degradation has been linked to cellular sensitivity 
to CPTs [17]. ScSV3 and ScH8 cells were treated with 
irinotecan and subjected to sub G1 analysis after 72 hours. 
The results clearly demonstrate that DNA-PKcs deficient 
cells are very sensitive to irinotecan (Figure 2I and 2J). 
We next determined cellular sensitivity to SN-38 (active 
metabolite of irinotecan) in MO59J (DNA-PKcs-/-) and 
MO59K (DNA-PKcs +/+) cells. The results showed that 
in contrast to MO59K, MO59J cells are sensitive to SN-
38 (Supplementary Figure S1B). We also determined 
Figure 2: DNA-PKcs dependent topoI-S10 phosphorylation is required for topoI degradation in response to CPT. 
A. ScSv3 and ScH8 cells lysates were analyzed by immunoblot with anti-DNA-PKcs. B. ScSv3 and ScH8 cell lysates were analyzed by 
immunoblot analysis with anti-topoI and anti-β-actin. C. ScSv3 and ScH8 cells were harvested and mRNA was extracted. TopoI mRNA 
was quantitatively analyzed by RT-PCR. D. TopoI activity assays were performed by incubating supercoiled (SC) DNA in the presence 
of nuclear extract from ScSV3 and ScH8 cells, and subsequently separated by electrophoresis in the presence of ethidium bromide. The 
larger proportion of relaxed (R) DNA compared to supercoiled DNA (SC) indicates higher activity of topoI. E. ScH8 and ScSV3 cells were 
treated with 25µM irinotecan and harvested at 3h and 6h. Cells lysates were immunoblotted with anti-topoI and anti-β-actin. F. Results of 
three independent experiments described in E were quantitatively analyzed (mean +/- SD). G. HeLa cells were treated with irinotecan and 
irinotecan+DNA-PK inhibitor; NU7026 for six hours. Cell lysates were analyzed by immunoblotting with anti-topoI and anti-β-actin. Non-
treated cells were also analyzed. H. Results of three independent experiments described in I were quantitatively analyzed by densitometry 
(mean +/- SD). I. ScH8 and ScSV3 were treated with 20nM irinotecan for 72 hours and analyzed for DNA content /sub G1 analysis 
(indicated by arrow) by FACS. ScSV3 control and treated cells (upper panel) and ScH8 control and treated cells (lower panel). J. Results 
of three independent experiments described in G were quantitatively analyzed (mean +/- SD). 
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the basal topoI-pS10 level in DNA-PKcs-positive and 
DNA-PKcs deficient cells and their potential link to 
CPT response. Immunofluorescence analysis with anti-
topoI-pS10 demonstrated higher basal level of topoI-
pS10 in MO59K cells (Supplementary Figure S1C). 
Taken together, these findings indicated that DNA-PKcs 
dependent phosphorylation of topoI-S10 is critical for 
CPT-induced topoI degradation and a higher basal level 
of topoI-pS10 ensures rapid degradation of topoI and CPT 
resistance. 
BRCA1 binds and ubiquitinates topoI for 
proteasomal degradation
In our GST-topoI pull down experiment, a protein 
with a molecular mass of approximately 65 kDa was 
Figure 3: BRCA1 associates and ubiquitinates topoI. A. Control and CPT-treated (5 μM SN-38) HCT-15 cells were lysed and 
subjected to immunoprecipitation with anti-BRCA1. Immunoprecipitates were immunoblotted with anti-topoI. B. Control and CPT-treated 
(5 μM SN-38) HCT-15 cell lysates were subjected to immunoprecipitation with anti-topoI or IgG (control) and immunoprecipitates were 
immunoblotted with anti-BRCA1. C. GST and GST-BRCA1-BRCT were incubated with HCT-15 cell lysate. After extensive washing 
the adsorbates were analyzed by immunoblotting with anti-topoI. D. GST and GST- topoI (aa1-210) were incubated with HCT-15 cell 
lysates. After extensive wash the adsorbates were analyzed by immunoblot analysis with anti-BRCA1. E. GST-topoI was phosphorylated 
with DNA-PK and then incubated with purified E1, UbcH5c (E2), and BRCA1/BARD1 (E3) and without BRCA1/BARD1. The reaction 
products were immunoblotted with anti-ubiquitin. F. BT-474 cells were transduced with BRCA1 silencing lentivirus (shBRCA1) and 
scrambled sequence lentivirus (as control). Control and shBRCA1 cells lysates were analyzed by immunoblotting with anti-BRCA1 and 
anti-β-actin. G. Control and shBRCA1 BT-474 cells were treated with 5 μM SN-38 for 2h and 6h and the cell lysates were immunoblotted 
with anti-topoI and anti-β-actin. H. HCC1937 and HCC1937-BRCA1, cells were treated with 5 μM SN-38 for 30, 60 and 90 min. Cell lysates 
were immunoblotted with anti-topoI (upper panel) and β-actin (middle panel). Cell lysates were also subjected to immunoprecipitation with 
anti-topoI and immunoprecipitates were immunoblotted with anti-ubiquitin (lower panel). I. HCC1937-BRCA1 cells were treated with 5 
μM SN-38 and cell lysates were subjected to immunoprecipitation with anti-topoI. The immunoprecipitates were analyzed by immunoblot 
with the indicated antibodies. 
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identified by MS/MS analysis as BRCA1. The BRCA1 
polypeptide is approximately 220 kDa, however, in our 
pulldown experiment, a BRCA1 proteolytic fragment 
containing the BRCT domain associated with topoI 
was identified. To better understand the UPP-mediated 
topoI degradation in the response to CPT, we asked if 
phosphorylated topoI is an E3 ligase substrate of BRCA1. 
Co-immunoprecipitation and direct binding experiments 
were performed to further understand the interaction 
between topoI and BRCA1. Our results demonstrated 
that topoI associate with BRCA1 and that this complex 
formation is enhanced in cells that are treated with CPT 
(Figure 3A and 3B). Direct binding experiments using 
GST pull down analysis also demonstrated that the 
topoI amino terminal region domain binds directly with 
BRCA1-BRCT domain (Figure 3C and 3D)
To determine whether topoI is ubiquitinated by 
BRCA1 in response to CPT-induced DSB formation, 
we first determined whether topoI is ubiquitinated by 
BRCA1 in vitro. GST-topoI phosphorylated by DNA-
PK was incubated with the BRCA1/BARD1 heterodimer 
in the presence of ubiquitin-activating enzyme E1, 
ubiquitin conjugating enzyme E2 (UbcH5c) and ATP 
in ubiquitination buffer. The reaction products were 
analyzed by immunoblotting with anti-ubiquitin. The 
results demonstrated that BRCA1 ubiquitinates topoI in 
vitro (Figure 3E). We then asked if topoI is ubiquitinated 
by BRCA1 in cells. We silenced BRCA1 in BT-474 by 
shRNA (shBRCA1-BT-474) (Figure 3F) and asked if topoI 
degradation was inhibited in BRCA1 silenced cells. The 
results clearly demonstrated that topoI is degraded in the 
response to CPT in BT-474 wild-type cells. However, no 
topoI degradation was observed in shBRCA1-BT-474 cells 
after 6 hours of CPT treatment (Figure 3G). We extended 
the study in E3 ligase-deficient HCC1937 cells with 
BRCA1 deletion and HCC1937 cells stably expressing 
WT BRCA1 (HCC1937-BRCA1) (Supplementary Figure 
S2) and determined CPT-induced topoI degradation. 
Figure 4: Rate of topoI degradation determines the cellular response to CPT in triple negative breast cancer cells and 
colorectal cancer cells. A. Triple negative breast cancer cell lines, MDA-MB-231, SUM-52, BT-20 and BT-549 cells, were treated with 
5 μM SN-38 for 30, 60 and 90 min. Cell lysates were immunoblotted with anti-topoI (upper panel) and β-actin (middle panel) antibody. 
Cell lysates were also subjected to immunoprecipitation with anti-topoI and immunoprecipitates were immunoblotted with anti-ubiquitin 
(lower panel). B. MDA-MB-231, SUM-52, BT-20 and BT-549 cells were treated with different concentrations of SN-38 and were analyzed 
for percent growth by Celigo direct cell counting after 72 hours (mean +/- SD). C. Colon cancer cell lines, Colo 205 and HCT-15 cells, 
were treated with 20µM Irinotecan and the cell lysates were immunoblotted with anti-topoI and β-actin antibody. D. Colo 205 (green) and 
HCT-15 (red) cells were plated in a 96 well plate and treated with different concentrations of irinotecan for 72 hours. Cell viability was 
determined by MTT assay. 
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Our findings demonstrate that topoI is not degraded 
in HCC1937 cells. However, HCC1937-BRCA1 cells 
efficiently degraded topoI in the response to CPT (Figure 
3H, upper panel). We also determined the ubiquitination 
status of topoI in HCC1937 and HCC1937-BRCA1 cells. 
In contrast to HCC1937, pronounced topoI ubiquitination 
was observed in HCC1937-BRCA1 cells treated with 
CPT (Figure 3H, lower panel). We used a K-48 specific 
ubiquitin antibody to determine the type of topoI 
ubiquitination and the results indicated that ubiquitin is 
attached to topoI via lysine 48 for proteasomal degradation 
(Figure 3I). Taken together, these findings demonstrate 
that CPT induced topoI degradation is UPP mediated and 
topoI is ubiquitinated by BRCA1. 
CPT-induced rate of topoI degradation 
determines the CPT response
Multiple cell lines (triple negative breast cancer; 
TNBC; colorectal cancer; CRC and small cell lung cancer) 
were used to determined the rate of topoI degradation in 
the response to CPT. The data clearly demonstrates that 
the cells that degrade topoI rapidly are resistant to CPT 
(Figure 4 and Supplementary Figure S3). In TNBC cells, 
we determined the status of topoI ubiquitination, rate of 
degradation and sensitivity to CPT. Results demonstrate 
that topoI is ubiquitinated only in those cell lines that 
degrade topoI (MDA-MB-231 and SUM-52), while no 
ubiquitination was observed in BT-20 and BT-549 (Figure 
4A). Also, the data strongly indicate that the cells that 
degrade topoI rapidly are resistant to CPT while cells that 
fail to degrade topoI are sensitive to CPT (Figure 4B).
Figure 5: HCT-15 cells have higher basal level of topoI-pS10 and generating topoI-EGFP fusion cells. A. Colo 205 and 
HCT-15 cell pellets were fixed and subsequently embedded in paraffin. Slides were cut from the cell pellet and IHC staining with anti-
topoI-pS10 (upper panel) and anti-topoI (lower panel) was performed. B. A SpCas9-VQR variant plasmid and a sgRNA expression plasmid 
targeted to the hTOP1stop codon were co-transfected with a homologous recombination donor plasmid in HCT-15 cells to generate topoI-
EGFP fusion protein expressing cell lines. C. Single EGFP positive cells were sorted and grown, and several clones were selected and 
characterized by western-blot. Cells lysates were subjected to immunoblot analysis with anti-topoI (upper panel) and anti-β-actin (lower 
panel). D. Three clones (3H8, 4E7 and 4H8) were further characterized by determining topoI degradation. Cells were treated with 2.5μM 
SN38 for 3h and EGFP florescence intensity was quantitatively analyzed by plate reader. E. Cells from clone 4E7 (HCT-15 4E7) were 
treated with 2.5μM SN38 (active metabolite of irinotecan) for 3h. Cells were visualized by using a Leica S5 confocal microscope. 
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TopoI degradation and drug sensitivity are linked 
to topoI-S10 phosphorylation
We, as well as others, have shown that rapid 
degradation of topoI leads to CPT resistance [17]. Here, 
we have also demonstrated that DNA-PK mediated 
phosphorylation of topoI-pS10 is critical for CPT induced 
topoI degradation. We next asked if topoI-pS10 levels 
predict rapid degradation of topoI and CPT resistance 
in CRC cells. In response to CPT treatment, topoI was 
degraded rapidly in HCT-15 colon carcinoma cells 
while little, if any, degradation was observed in Colo 
205 cells. Cell viability data also indicated that HCT-
15 cells are at least ten fold more resistant to CPT than 
Colo 205 cells (Figure 4C and 4D). We then asked if 
the rate of degradation is linked to topoI-pS10 level. 
Immunohistochemistry (IHC) with our mouse monoclonal 
antibody (Clone 1C1.H5.H7) demonstrated a strong topoI-
pS10 nuclear staining in HCT-15 cells. In contrast, few 
topoI-pS10 positive cells were seen in Colo 205 cells 
(Figure 5A upper panel). IHC assays were also performed 
using anti-topoI and data demonstrates that topoI protein 
level is similar in Colo 205 and HCT-15 cells (Figure 5A, 
lower panel). These results were consistent with higher 
topoI-pS10 indicates rapid topoI degradation and CPT 
resistance. 
Developing a gene edited cell line to quantitatively 
analyze CPT induced topoI degradation
To summarize, our studies have revealed that, i) 
topoI is rapidly degraded in CPT-resistant cells, ii) higher 
basal levels of topoI-pS10 ensures rapid degradation of 
topoI and thus cause CPT resistance and iii) that DNA-
PK phosphorylates topoI at S10. To better understand CPT 
resistance mechanisms, it therefore became imperative to 
understand the upstream regulation of DNA-PKcs. To 
visualize topoI degradation in the response to CPT in real 
time, we fluorescently tagged topoI in HCT-15 cells. An 
endogenous fusion to EGFP was generated using CRISPR/
Cas9 genome editing in the presence of a homologous 
recombination donor that resulted in integration of 
EGFP at the C-terminus of the hTOP1 gene (Figure 5B). 
Following puromycin selection, single EGFP positive cells 
were sorted and grown, sequence analysis confirmed the 
integration of EGFP at the C-terminal end of the hTOP1 
gene (data not shown). A change in the molecular mass 
of approximately 24kDa indicates the integration of 
EGFP into topoI (Figure 5C). Clonal topoI-EGFP cell 
lines enabled us to achieve two specific goals: first, to 
quantitatively analyze topoI degradation in the response 
to CPT, and secondly, it provided an efficient assay to 
identify the potential upstream regulators of DNA-PKcs.
It has also been established that CPT induces rapid 
nucleolar clearance of topoI [25]. We therefore asked 
if our genetically-edited cells have these functional 
attributes. Three topoI-EGFP integrated HCT-15 cell 
clones, 3H8, 4E7 and 4H8 were treated with 2.5μM SN-
38 and florescence intensity was quantitatively-analyzed 
(Figure 5D). Nuclear re-localization of topoI-EGFP was 
observed by confocal microscopy, which was consistent to 
the previous report [26]. A significant reduction in topoI-
EGFP signal and rapid nuclear re-localization of topoI-
EGFP in CPT-treated cells was observed in all the clones 
(Figure 5E). To further confirm topoI function in genome 
edited cell lines, we determined the CPT sensitivity by 
clonogenic survival assays. As expected, a comparative 
analysis indicated that HCT-15 cells are more resistant to 
HCT-116 cells (both genetically edited). (Supplementary 
Figure S4). These findings confirmed that the topoI-EGFP 
fusion protein follows the functional pathway of WT topoI 
protein in genetically edited cells. Based on this and other 
data, we selected clone 4E7 for our siRNA library screen 
experiments. 
iRNA library screen to identify upstream 
regulators of DNA-PKcs in response to CPT
We have demonstrated that a higher basal level 
of topoI-pS10 ensures topoI ubiquitination and rapid 
proteasomal degradation of topoI, leading to CPT 
resistance. These findings indicated that in these 
cells, DNA-PKcs remains active and ensures a higher 
basal level of topoI-pS10. Phosphorylation and de-
phosphorylation have been a primary mechanism of 
DNA-PKcs activation and inactivation. DNA-PKcs is 
activated by recruitment to DSBs, via Ku70/80. Once 
activated, autophosphorylation causes subsequent 
inactivation of DNA-PK and dissociation from DSB ends 
[27, 28]. Protein phosphatases have been shown to interact 
with DNA-PKcs and could serve as potential upstream 
regulators of DNA-PKcs [29]. However little is known 
regarding this aspect in the literature and the mechanism 
is not well defined. Using HCT-15 4E7 cells, we asked 
if nuclear phosphatases regulate CPT-induced topoI 
degradation. We preformed an siRNA library screen of 56 
reported nuclear phosphatases, and phosphatase silenced 
cells were treated with CPT. GAPDH siRNA was used as 
a control. Silencing of nuclear phosphatase genes affected 
topoI degradation (Supplementary Figure S5). Based on 
the data from the first screen, we selected 9 genes that 
enhanced topoI degradation the most, as well as the 9 
genes that contributed least. Thus, in the second phase of 
the siRNA library screen, we used only 19 selected genes 
(including one control) to determine the effect of specific 
phosphatases in CPT-induced topoI degradation. 
Relative intensity of GFP fluorescence was 
measured after 4 hours of CPT treatment and the mean 
level of GFP fluorescence was also determined. We then 
calculated the z score using the formula (mean gene-
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mean control)/sd (control). Bonferonni corrections were 
used to determine significance threshold (p = 0.0025). 
Genes showed both positive and negative z-scores. The 
positive z-scores indicated that topoI degradation was 
stabilized after silencing the specific gene. Silencing of 
CDC 14B showed the least topoI degradation although not 
significantly different compared to control (Figure 6A). 
Silencing of several genes increased the degradation of 
topoI, indicated by negative z-scores. Genes DUSP10, 
NUDT1 and PPTRE showed marginally significant 
reduction (p = 0.04), and gene DUSP11 showed more 
pronounced reduction beyond control (p = 0.003). 
Silencing of genes CTDSP1 and PTEN showed a 
statistically significant (Bonferonni corrected threshold) 
reduction in GFP florescence relative to control (p < 
0.0001) (Figure 6A). 
PTEN dephosphorylates DNA-PKcs and PTEN 
deficient cells have higher basal level of topoI-
pS10
DNA-PKcs is activated and inactivated 
by phosphorylation. Although the full effects of 
phosphorylation and kinase inactivation remain to be 
understood, autophosphorylation of serine 2056 (pS2056) 
has been shown to be a reliable indicator of DNA-PKcs 
activation [30]. Our siRNA screen data indicates that 
silencing PTEN significantly enhanced topoI degradation 
in response to CPT and that DNA-PKcs dependent topoI-
pS10 is higher in these cells. We first asked whether 
PTEN dephosphorylates DNA-PKcs. A DNA-PKcs 
autophosphorylation kinase assay was performed, and at 
the completion of the assay purified PTEN was added. 
Our results demonstrate that addition of PTEN resulted 
in dephosphorylation at S2056 (Figure 6B). We used a 
MDA-MB-231 cell line with stably silenced PTEN by 
shRNA (PTEN shRNA) (Supplementary Figure S6A) 
and control C2 cells and asked if there is any difference 
in the basal level of phospho-DNA-PKcs and topoI-
pS10. PTEN shRNA cells showed a higher basal level 
of DNA-PKcs-S2056 and topoI-S10 phosphorylation 
(Figure 6C and Supplementary Figure S6B). Since 
we have demonstrated that higher basal level ensures 
rapid degradation of topoI in response to CPT, we next 
asked whether this is controlled by PTEN. C2 and 
PTEN shRNA cells were treated with SN-38 and cell 
lysates were immunoblotted with an anti-topoI antibody. 
PTEN-deficient cells with higher levels of phospho 
DNA-PKcs and phospho-topoI showed a rapid rate of 
topoI degradation compared to control cells (Figure 6D 
and 6E). These results were further confirmed by the 
immunostaining of cells with an anti-topoI antibody 
(Figure 6F and 6G). One of most distinct functional 
validations of topoI degradation is the cellular sensitivity 
to CPT. We asked if PTEN shRNA cells that rapidly 
degrade topoI are resistant to CPT. Clonogenic survival 
assays and subG1 analysis by FACS were performed and 
our data indicates that PTEN shRNA cells are indeed more 
resistant to CPT (Figure 6H and 6I). 
DISCUSSION
Human topoI, a type IB enzyme, reduces DNA 
supercoiling by cutting and re-ligation of a single DNA 
strand. The cutting and re-ligation of DNA is achieved 
by two transesterification reactions. In the first reaction, 
topoI-723 tyrosyl attacks the DNA phosphate group 
causing a DNA strand break and tyrosyl oxygen is 
covalently linked to the 3’ phosphate group of DNA. 
The second transesterification causes the reversal of the 
first reaction leading to rejoining of the broken strand. A 
controlled rotation, between the cutting and the re-ligation 
reduces the supercoiling [2]. However, in the presence 
of CPT, the re-ligation step is blocked, resulting in an 
accumulation of covalent reaction intermediates, referred 
Figure 6: DNA-PKcs dependent topoI-S10 phosphorylation is regulated by PTEN. A. A siRNA screen was performed in 
two phases, in the first phase 56 nuclear phosphatases were silenced using siRNA library (GE-Dharmacon). Phosphatases were silenced 
in HCT-15 4E7 cells and cells were treated with 2.5μM SN-38 for 4h. EGFP florescence intensity, indicating rate of topoI degradation, 
was analyzed using a plate reader. Multiple silencing experiments were performed using the 18 genes that most affected the topoI-EGFP 
degradation. The most and least significant phosphatases are listed. Bar graph shows the Z-score of the most and the least significant 
effect on topoI degradation in response to CPT. CTDSP1 and PTEN were identified as the most significant phosphatases inhibiting topoI 
degradation. B. DNA-PKcs kinase reactions were performed with or without DNA-PKcs inhibitor and PTEN. The reaction products were 
analyzed by immunoblot analysis with a phosphospecific antibody to DNA-PKcs-S2056. C. C2 and PTEN shRNA cells were stained 
by immunofluorescence with phosphospecific anti-DNA-PKcs-S2056 and anti-topoI-pS10 antibodies. D. To determine the rate of topoI 
degradation, C2 and PTEN shRNA cells were treated with 2.5μM SN38 for 90 and 180 min. Cell lysates were immunoblotted with 
anti-topoI (upper panel) and anti-β-actin (lower panel). E. Quantitative estimation of topoI protein in C2 and PTEN shRNA cells treated 
with SN-38 in Figure 6D. * P < 0.01. F. C2 and PTEN shRNA cells were treated with 2.5µM SN-38 for 90 and 180min. The TopoI 
protein level was determined by immunofluorescence staining with anti-topoI (red). G. Graph shows a quantitative estimation of topoI 
immunofluorescence labeled with topoI in C2 and PTEN shRNA cells in Figure 6F. * P < 0.01. H. C2 and PTEN shRNA cells were treated 
with various concentrations of SN-38 and clonogenic survival assays were performed. Colonies were counted and relative number of 
colonies was determined. I. C2 and PTEN shRNA cells were treated with SN-38 at indicated concentration for 24 hours. After 72 hours of 
incubation, cells were harvested and analyzed for DNA content /sub G1 analysis by FACS. Results of three independent experiments were 
quantitatively analyzed (mean +/- SD). ** P < 0.0001. 
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to as the cleavable complex. The formation of cleavable 
complexes leads to stalled replication forks, and ultimately 
DSBs [1]. The crystal structure of the topoI-DNA-CPT 
complex indicates that topotecan (a CPT analogue) mimics 
a DNA base pair and binds to the complex between the 
DNA bases of both-strands at the DNA cleavage site 
[31]. This complex block not only the re-ligation step, 
but also access to the 3’-termini required for loading 
of protein complexes for DNA repair. In human cells 
DSBs are repaired by two main pathways, NHEJ, which 
is initiated by recruitment of Ku and DNA-PKcs and is 
active throughout G1, S and G2 [32] and homologous 
recombination (HR), which is active only in S and G2. 
HR -mediated repair begins with resection of the DNA-
DSB by MRN complex to create a long stretch of single 
stranded (ss) DNA with a 3’end for recruitment of RPA 
which initiates recruitment of Rad51 for HR [33]. 
CPT-induced DNA-DSB is unique and the precise 
mechanism of early DDR is not understood. The strand 
breaks are single-ended double strand breaks, topoI 
polypeptide is linked to 3’ of the broken strand and broken 
strand with repair available 5’ is a collapsed replication 
fork. Pathway choice, in single-ended double-strand 
breaks, between most prevalent NHEJ and S-phase 
specific HR-mediated repair is yet to be defined. The MRN 
complex plays a central role in pathway determination. 
Mre11 endonuclease activity nicks adjacent to DSB. 
Subsequently, resection proceeds in both directions via 
Figure 7: Schematic representation of UPP mediated degradation of topoI in response to CPT.
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Mre11 3’-5’ and Exo1/BLM 5’-3’ exonuclease activity 
[34]. However, this model is based on XRT induced 
single-ended DNA-DSB. This model does not explain 
the resolution of complexity rendered by CPT induced 
single-ended DSB, particularly how topoI is removed and 
the collapsed replication fork is restored. In S. cerevisiae, 
Mre11 mutant sensitivity in the response to CPT is 
suppressed in Ku70 deleted cells, indicating interplay 
between these two proteins at single ended DSBs. This 
interplay determines the extent of Exo1- dependent 
resection at the 5’ of the broken strand [35]. DT40 
chicken cells deficient in Ku80 are resistant to CPT [36, 
37]. Similarly, in CHO cells, Ku80 deficient cells were 
not CPT sensitive [38]. However, in this study, Shin et 
al. used high concentration CPT (1μM) for short duration 
(only 30 minutes) and relatively low concentration (100 
nM CPT) for longer duration. These concentrations do 
not conclusively address the role of Ku80 in CPT-induced 
DDR. We have demonstrated that topoI associates with 
DNA-PK and DNA-PKcs phosphorylates topoI for 
ubiquitination and proteosomal degradation. Thus, our 
work indicates that NHEJ sensor complex stabilizes the 
broken strand and initiates the removal of topoI for repair. 
Our findings are in concert with reports on the activation 
of DNA-PKcs by CPT [39, 40]. The role of DNA-PK in 
CPT induced DNA-DSB is further supported by our data 
demonstrating that DNA-PKcs deficient cells are sensitive 
to CPT (Figure 2 I , J and Supplementary Figure S1B).
BRCA1 plays a critical role in genome maintenance 
[41]. Critical to its many functions is its association with 
various protein complexes involved in DSB repair [42]. 
However, the precise mechanism by which BRCA1 
functions in DSB repair is still not well understood. 
Here, we use three different approaches (highly purified 
in vitro ubiquitination assays, silencing of BRCA1, 
and expressing BRCA1-WT in HCC-1937 cells) to 
demonstrate that BRCA1 ubiquitinates topoI in vitro 
and in cells. In an effort to understand BRCA1 E3 ligase 
function in DNA-DSB, Reid et al. generated isogenic 
clones of embryonic stem cells with BRCA1-WT, I26A (a 
mutant that only impairs BRCA1 E3 ligase function and 
not BRCA1-BARD1 interaction), and a BRCA1 deletion 
mutant that affects BRCA1 DDR function significantly. 
Using mitomycin C (MMC) and ionizing radiation (IR), 
they demonstrated that E3 ligase deficient cells are not 
sensitized to these agents, and that the rates of homology 
directed DNA-DSB repair are similar [43]. In striking 
contrast, BRCA1-E3 ligase inactivation impairs the 
DDR when CPT is used as the DNA damaging agent 
in DT40 chicken cells. In these cells, V26A abrogates 
the E3 ligase activity of BRCA1. Cell viability, Rad51 
foci formation and sister chromatid exchange (SEC) 
rates were all similar in BRCA1 WT and V26A cells in 
response to MMC. However, V26A mutant cells were very 
sensitive to CPT, with a sharp reduction in RAD51 foci 
formation and SEC frequency [44]. Collectively, these 
studies demonstrate that BRCA1 E3 ligase function is 
critical only for CPT-induced DDR. Our findings not only 
support these observations, but also define the mechanism 
for this specificity. Specifically, we show that HCC1937 
cells, with BRCA1 deletion, fail to degrade topoI and are 
sensitive to CPT while HCC1937 cells reconstituted with 
BRCA1 WT degraded topoI in response to CPT and are 
resistant to CPT. Significantly, we show that CPT induced 
topoI ubiquitination and degradation is directly linked 
to CPT response as demonstrated in four TNBC cells. 
Taken together, we conclude that BRCA1 is the E3 ligase 
for topoI, and the rate of topoI proteasomal degradation 
determines CPT response. 
Our findings demonstrating CPT-induced 
proteasomal degradation of topoI is in agreement with 
published literature. The literature also demonstrates 
that topoI is degraded differentially in cancer cells and 
CPT response depends on the rate of topoI degradation. 
We have replicated these findings in ten cancer cell 
lines representing CRC, TNBC and SCLC (Figure 3 
and Supplementary Figure S3). However, one of our 
most important findings is to demonstrate that the basal 
level of topoI-pS10 is critical for topoI ubiquitination. 
The implications of these findings are as follows: first, 
we understand the molecular mechanism of topoI 
ubiquitination and more importantly topoI-pS10 is a 
molecular determinant for CPT-induced rate of topoI 
degradation and drug response. The higher basal level of 
topoI-pS10 predicts the rapid rate of topoI degradation and 
cellular resistance to CPT. In contrast, cells with lower 
levels of topoI-pS10 fail to degrade topoI, resulting in 
impaired DDR and cell death. 
We have demonstrated higher basal cellular level 
of topoI-pS10 in cancer cell lines, and various tumor 
types. These findings also indicate that the cells with 
higher basal level of topoI-pS10 have higher DNA-PKcs 
kinase activity (inferred from increased DNA-PKcs S2056 
phosphorylation). There are three potential mechanisms 
for DNA-PKcs regulation: DDR related activation and 
inactivation, changes in protein expression and upstream 
phosphatases. Activation of DNA-PKcs in response to 
DSBs is relatively well understood and higher levels of 
DNA-PKcs expression have been reported in various 
tumor types including CRC, linking them to tumor 
pathogenesis and tumor progression, [45-49]. DNA-
PKcs has also been identified as selective regulator of 
transcription leading to prostate cancer progression and 
metastasis. DNA-PKcs is up regulated and activated 
significantly in advanced disease. This activation was 
independent of its DDR activities and it correlated with 
tumor metastasis, recurrence and poor survival [50]. IHC 
analysis of tumor microarray slides representing CRC, 
breast, ovarian and SCLC shows differential topoI-pS10 
independent of stage of the tumor (Supplementary Figure 
S7). This suggests that the topoI-pS10 level depends 
on DNA-PKcs non-DDR activation and also on tumor 
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progression dependent higher DNA-PKcs protein level. 
Protein phosphatases have been suggested as the potential 
upstream regulators of DNA-PKcs [29] but the mechanism 
is not well defined. Here, we identify PTEN as a novel 
potential DNA-PKcs regulatory phosphatase. PTEN 
is a tumor suppressor gene that possesses both protein 
and lipid phosphatase activity. The lipid phosphatase 
activity is linked to tumor suppressor, whereas the protein 
phosphatase activity is regulatory in nature [51]. PTEN 
is a dual phosphatase, as it can dephosphorylate protein 
and peptide substrates phosphorylated on serine, threonine 
and tyrosine [52]. Our library screen data was confirmed 
by using stably PTEN silenced MDA-MB-231 cells. 
PTEN shRNA cells had a higher level of phosphorylated 
DNA-PKcs (S2056) and topoI-pS10. Thus, various 
lines of evidence demonstrated that PTEN is one of 
the upstream effectors in DNA-PKcs dependent topoI 
proteasomal degradation pathway. This observation was 
further confirmed by our findings that PTEN phosphatase-
deficient cells degrade topoI rapidly and are resistant to 
CPTs. Further studies would be required to understand a 
potential universal link between PTEN tumor suppressor 
mechanisms and drug resistance. However, our data 
indicates that deletion of tumor suppressor PTEN imparts 
CPT resistance, enhances the survival and ultimately 
tumor progression.
In sum, CPT-induced proteasomal degradation 
of topoI determines CPT response; a higher basal level 
of DNA-PKcs dependent topoI-pS10 ensures rapid 
degradation and CPT resistance. BRCA1 E3 ligase 
function is critical in this pathway and PTEN is one of the 
upstream effector of this pathway (Figure 7).
MATERIAL AND METHODS
Tissue culture
Cell maintenance and growing
Mouse embryo fibroblasts (MEF) reconstituted for 
stable expression of DNA-PKcs (SCH8, DNA-PK +/+), 
wild type scid mice MEF (ScSV3, DNA-PK -/-) were 
kind gifts from Dr. Frederic Alt lab. HeLa cells, HCT-
15 cells, BT-474 cells, HCC-1937 cells, MDA-MB-231 
cells, SUM-52 cells, BT-549 cells, BT-20, HCT-116, Colo 
205, H69, H249 and H526 were obtained from ATCC. 
MO59K cells and MO59J cells were kind gifts from Dr. 
Lees-Miller lab. SCH8 cells, ScSV3 cells, HeLa cells 
and MDA-MB-231 cells were grown and maintained 
in DMEM containing 10% fetal bovine serum, 2mM 
L-Glutamine, 100 units/ml of Streptomycin and 100 units/
mL of Penicillin. HuMEC supplement (Invitrogen) was 
also used for SUM52 cells. BT474 cells, BT-549 cells, BT-
20 cells, HCC-1937 cells, HCT-15 cells, HCT-116 cells, 
Colo 205 cells, H69 cells, H249 cells and H526 cells were 
maintained in RPMI containing 10% FBS and pen-strep. 
MO59K and MO59J cells were maintained in DMEM/
F12 containing 10% FBS, 1mM MEM sodium pyruvate, 
0.1mM NEAA and pen-strep. All cells were grown at 
37°C and 5% CO2 in a humidified cell culture incubator.
Cell synchronization
MEF cells were phase-synchronized by serum 
starvation. Cells were incubated for 30 hours in DMEM 
containing 0.1% FBS followed by 16 hour incubation in 
complete medium containing 10% FBS.
Drug treatment
TopoI inhibitor treatment was performed using 
various concentrations of either irinotecan (Sigma-
Aldrich) or SN-38 (Tocris). Cells were treated with 0.5 
µM DNA-PK inhibitor NU7026 (EMD-CALBIOCHEM). 
Cell viability assay
In order to measure cell growth inhibition with 
the addition of CPTs, a Celigo (Cyntellect, Inc.) cell 
counting machine was used. Cells were incubated in a 
Hoechst 33258 dye for 15 minutes and between 5,000 
and 10,000 cells per well were plated in a black 96-well 
plate (Corning), according to cell doubling time and size. 
An initial baseline cell count was taken 24 hours after 
plating and averaged over the entire 96 wells, giving a 
time zero count (Tz). Following the initial reading, the 
plate was divided into 16-wells each of control, 10 nM, 
25 nM, 50 nM, 100 nM and 200 nM SN-38 treatments. 
The drug was replaced by fresh media after 24 hours 
of treatment. 72 hours following initial treatment of the 
cells, the plates were once again read using the Celigo 
fluorescent cell counting machine. Control growth (C) was 
then calculated by taking the average of the 16 control 
wells and subtracting by the overall plate Tz average. 
Test growth (Ti) was similarly averaged of 16 wells and 
subtracted from the plate Tz average. Overall percentage 
growth inhibition for each of the drug concentration levels 
was calculated using a formula adopted from the NCI in 
vitro cancer drug screen, where:
 [(Ti-Tz)/(C-Tz)] x 100 for concentrations for which 
Ti ≥ Tz
 [(Ti-Tz)/Tz] x 100 for concentrations for which Ti 
< Tz.
Improvised GST pull down
An improvised GST pull down experiment was 
performed as described [21], and performed as follows: 
GST fusion protein attached sepharose bead 
preparation
Purified GST (control) and GST-topoI were eluted 
from glutathione sepharose beads by elution buffer (10 
Oncotarget43746www.impactjournals.com/oncotarget
mM reduced glutathione, 150mM NaCl, 50 mM Tris, pH 
8.0). The eluted protein was dialyzed in PBS for twelve 
hours at 4°C. Protein concentration of dialyzed samples 
was determined by modified Bradford reagent (Bio-Rad). 
The eluted and dialyzed GST and GST-topoI protein was 
incubated with glutathione sepharose beads. 1.5 gm. 
of GST and GST-topoI were reattached to 1ml of GS 
beads. The reattached, PBS equilibrated GST and GST-
topoI beads were poured into two empty columns, the 
columns were washed with PBS and used for pull down 
experiments.
Nuclear isolation
4x108 cells were harvested. The cell pellet was 
re-suspended in buffer A (10 mM Hepes pH7.8, 10mM 
KCl, 0.1mM EDTA, 1mM DTT) with protease inhibitor 
cocktail (Roche). Cells were incubated for 10 minutes on 
ice and centrifuged for 5 minutes at 1500 g. The cells were 
resuspended in buffer A and homogenized (10-12 strokes) 
with type A hand held homogenizer. The homogenate was 
centrifuged at 1500g for five minutes, and the nuclear 
pallet was collected for protein extraction.
Nuclear extract
The nuclei was resuspended in buffer B (50 mM 
Hepes pH 7.8, 420mM KCl, 0.1mM EDTA, 5mM MgCl2 
, 1mM DTT and 2% glycerol with protease inhibitor 
cocktail). The resuspended nuclei were rotated for 30 
minutes at 4°C and the nuclear extract was collected after 
centrifugation at 24,000g for 30 minutes. The nuclear 
extract was dialyzed in buffer C (30mM Tris pH 7.4, 5mM 
MgCl2, 1mM EDTA and 1mM DTT) for 20 hours with two 
buffer changes.
Protein complex isolation
An equal volume of the dialyzed nuclear extract 
was passed through GST and GST-topoI columns after 
equilibrating them with buffer C. The step was repeated 
three times to provide sufficient time for proteins in the 
extract to bind with GST and GST-topoI. The column 
was washed with twenty volume of buffer C. After 
the completion of the wash, 1 ml of buffer D (buffer 
C+150mM NaCl) was added to elute the interacting 
proteins. The eluted proteins were collected in five 
fractions of 200µl each. The proteins were further eluted 
and fractionated with 1 ml of buffer E (buffer C+500mM 
NaCl). The fractions containing topoI interacting proteins 
were analyzed by SDS-PAGE and silver staining.
GST-topoI-deletion mutations
As described previously [53]. 
BRCA1 silencing
Virus production
BRCA1 shRNA and control plasmids were 
purchased from Open Biosystems. All pLKO.1 plasmids 
were developed by the RNAi consortium (Boston, MA). 
Packaging and envelope plasmids were obtained from 
Addgene (Cambridge, MA). To produce virus, pLKO.1 
plasmids, the packaging plasmid psPAX2, and the 
envelope plasmid pCMV-VSVg were simultaneously 
transfected into 293FT cells (Invitrogen). 18 hours after 
transfection, media was replaced with DMEM containing 
30% FBS. Virus containing media was subsequently 
removed in 2 aliquots at 24 and 48 hours and frozen at 
-80°C.
Viral transduction
Virus transduction was completed by adding the 
appropriate amount of virus-containing media and 8µg/
mL hexadimethrine bromide to growth media containing 
non-attached cells. Upon completion of transduction and 
attachment 24 hours later, virus-containing media was 
removed and replaced with fresh media containing 2.5 µg/
mL puromycin. Transduced cells were selected for at least 
2 days before use. Transduction efficiencies exceeded 95% 
in most cell types.
The following TRC designated plasmids were 
tested: TRCN0000039833, TRCN0000039834, 
TRCN0000039835, TRCN0000039836, and 
TRCN0000039837. It was determined that 
TRCN0000039834 resulted in the greatest knockdown.
Immunoprecipitation and immunoblot analysis
As described previously [53].
In vitro phosphorylation
Purified GST-topoI was incubated with DNA-PK in 
kinase buffer (20 mM Tris-HCl, pH 7.4, 10 mM MgCl2 
and 10 mM MnCl2) containing [γ32P]ATP or cold ATP 
for 30 min at 30°C. The reaction products were analyzed 
by SDS-PAGE and autoradiography. Selected reaction 
products were also used for in vitro ubiquitination 
experiments.
Protein identification by mass spectrometry
Proteins from coomassie/silver stained gels were 
excised and in gel digested as previously described 
[54]. Trypsin digested proteins were analyzed by mass 
spectrometry. 
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Phosphopeptide enrichment for mass 
spectrometry
Following tryptic digestion of the protein, 
immobilized metal affinity chromatography (IMAC) 
was performed to enrich phosphorylated peptides as 
previously described [55]. Briefly, tryptic peptides were 
loaded onto a self-packed IMAC column (in fused silica 
capillary, 100 µm I.D., 10cm length) charged with Fe3+. 
Non-phosphorylated peptides were removed by rinsing 
with 20 µL of 25% acetonitrile in 100 mM NaCl. Peptides 
retained on the IMAC column were eluted with 250 mM 
sodium phosphate (pH 8.0) and loaded onto a reverse-
phase C18 pre-column (100 µm I.D. x 10 cm length), 
which was then rinsed with 10 µL of 0.2 M acetic acid 
to remove phosphate buffer. After rinsing, the pre-column 
was attached to a reverse-phase C18 resolving column (50 
µm I.D., 10 cm length) with an integrated electrospray tip. 
Peptides were then eluted from the column and analyzed 
by electrospray ionization liquid chromatography tandem 
MS on a QqTof mass spectrometer (QSTAR Elite, Applied 
Biosystems). MS/MS spectra of the five most intense 
peaks with 2 - 5 charge states in the full MS scan were 
acquired in information-dependent acquisition. 
Phosphopeptide sequencing and quantification
MS/MS spectra were extracted and searched using 
MASCOT (Matrix Science) against the human non-
redundant protein database with trypsin specificity, two 
missed cleavages, precursor mass tolerance of 2.2 amu for 
the precursor ion and 0.15 for the fragment ion tolerance. 
Phosphorylation sites and peptide sequence assignments 
were validated and quantified by manual confirmation of 
raw MS/MS data.
In vitro ubiquitination
Reactions on 700 ng of topo I were carried out in 
10 mM HEPES (pH 7.9), 0.5 mM EDTA, 5 mM MgCl2, 
2 mM NaF, 2 mM ATP, 60 mM KCl, 1 µM ubiquitin, 200 
nM E1-His, 5 µM UbcH5c-His (E2) and 200 to 400 ng 
of BRCA1-Flag/BARD1 (E3). Negative controls were 
also established in the absence of BRCA1-Flag/BARD1. 
Reaction products were analyzed by SDS-PAGE and 
autoradiography.
Development of HCC-1937 BRCA1 stable cell line
HCC-1937 cells with a known mutation in the 
BRCA1 gene yielding a truncated and non-functional 
BRCA1 protein were transduced with lentivirus containing 
the full-length wild type (WT) BRCA1. Following 
infection, the cells were selected for blasticidin resistance. 
Two colonies were finally selected and BRCA1 expression 
was confirmed by immunoblot with anti-BRCA1 antibody 
(Santa Cruz, CA) (data not shown). 
TopoI ubiquitination in cells
Following 30 minutes of MG-132 (5 μM) treatment, 
cells were treated with 1 μM SN-38 for 30 minutes. Cells 
were lysed according to the procedure described [16]. 
Briefly, cells were lysed in 0.2 N NaOH with 2 mM 
EDTA. Cell lysates were then sonicated and neutralized 
with 2N HCl, followed by the addition of 10% Nonidet 
P-40, 1M Tris, pH 7.4, 0.1 M MgCl2, 0.1M CaCl2, 10 
mM dithiothreitol, 1 mM EGTA, and 100 μg/ml of each 
leupeptin, pepstatin, and aprotinin. Micrococcal nuclease 
(10 μg/ml) was added and incubated for 30 minutes at 
room temperature. Reactions were stopped by the addition 
of 0.1 M EGTA. Micrococal nuclease treated cell lysates 
were subjected to immunoprecipitation using scleroderma 
patient serum (containing high anti-topoI titer). Protein 
A bound magnetic nanoparticles (Miltenyi) were then 
added to the lysate and further rotated for 1 hour at 4°C. 
Immunoprecipitates were washed with low salt buffer 
using a magnetic column (Miltenyi). Immunoprecipitates 
were eluted from the column and analyzed by immunoblot 
analysis with pan or lysine-specific (K-48 or K-63) anti-
ubiquitin antibodies (Cell Signaling, MA), as well as anti-
topoI (BD Biosciences). 
Developing topoI-pS10 phosphospecific 
monoclonal antibody
Mouse monoclonal antibody against topoI-pS10 was 
produced and purified at the hybridoma core facility of 
Dana-Farber Cancer Institute, Boston. A phosphopeptide 
containing the N-terminus of topoI with phosphoserine 
10 was used to raise the antibody. Several clones were 
screened by ELISA assays and 10 clones were selected 
and screened for IHC. After the screen, clone 357.3.1C1.
H5.H7 was finally selected for large volume culture and 
purification of the antibody. 
Integrating EGFP following the hTOP1 gene in 
HCT-15 cells
Summary sequences of plasmids used in this study 
can be found in Supplementary Table 1. Roughly 1000 
bases 5’ and 3’ of the genomic sequence flanking the last 
hTOP1 exon in HCT-15 cells were sequenced to identify 
and account for any cell-type specific polymorphisms. 
To do so, multiple PCR products spanning the genomic 
sequence were amplified using Phusion DNA Polymerase 
(New England Biolabs). The resulting PCR amplicons 
were cloned using the Zero Blunt TOPO PCR Cloning Kit 
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(Invitrogen), transformed into E.coli XL-1 blue competent 
cells, and ~20-25 colonies were grown overnight at 37°C 
in TB media prior to miniprep and sanger sequencing 
(MGH DNA Core). A single guide-RNA (sgRNA) 
targeting the hTOP1 stop codon was designed so that 
the SpCas9 binding site would be destroyed following 
gene conversion. To generate the sgRNA plasmid, 
oligonucleotides corresponding to the spacer sequence 
of the target site were annealed and ligated into BsmBI 
cut BPK1520 [56]. The homologous recombination donor 
plasmid designed to create the topoI-EGFP fusion protein 
was generated by Gibson assembly into the NheI and 
HindIII sites of pUC19. Regions of the genomic sequence 
5’ and 3’ of the hTOP1 stop codon were assembled with 
an EGFP-P2A-Pac (for puromycin resistance) fusion 
cassette to generate the final donor plasmid (with 5’ and 
3’ homology regions of 934 and 824 bases, respectively). 
Transfections into HCT-15 cells were performed by 
lipofectamine(Thermo Fisher Sceintific) with: 1) 2µg 
of a wild-type Streptococcus pyogenes Cas9 expression 
plasmid (MSP469) [56], 2) 1µg of the sgRNA expression 
plasmid (MMW134) and 3) 2µg of the homologous 
recombination donor plasmid (MMW274). After 7 
days of the transfection, cells were selected with 4µg/
ml puromycin. After 14 days of selection, the cells were 
sorted by MoFlo Legacy (Beckman Coulter). The sorted 
cells were maintained in 2µg/ml puromycin contained 
media. Precise incorporation of the genome editing 
cassette in single cell cloned HCT-15 hTOP1-EGFP 
cells was confirmed by PCR amplifying the genomic 
locus and sequencing. Also, western blot analysis and 
immunofluorescence was done to characterize the genome 
edited cells (Figure 4 D and E). 
Quantifying EGFP intensity by plate reader
Genome edited topoI-EGFP HCT-15 cells were 
grown in 96 well plate black clear bottoms. Cells were 
treated with 2.5µM SN38 for indicated time points. Then 
the media was changed to PBS and EGFP intensity was 
measured by plate reader (Tecan). 
DNA-PKcs kinase assay
0.05µg of DNA-PKcs and 0.03µg of Ku70/80 
were incubated with double-strand DNA in kinase 
buffer (50mM HEPES pH 7.5, 10mM MgCl2, 75mM 
KCl and 0.2mM ATP) for 30mins at 30°C. Then DNA-
PK inhibitor; NU7026 was added and incubated for 
5mins at room temperature. Then PTEN was added and 
incubated for 30mins at 30°C. The proteins were boiled in 
an SDS sample buffer and separated by SDS-PAGE (5% 
polyacrylamide) and analyzed by immunoblotting with 
anti-phospho DNA-PK S2056 antibody.
Immunofluorescence
Cells were grown on a sterilized coverslip. After the 
treatment, the coverslip was washed twice with ice cold 
PBS, fixed with 3.7% formaldehyde, and permeabilized 
with 0.2% Triton X-100. After blocking with 3% BSA for 
60 minutes, the coverslip was incubated with monoclonal 
anti-phospho DNAPK S2056 (abcam) antibody, 
monoclonal anti-topoI antibody (BD) or monoclonal 
anti-phospho topoI S10 antibody followed by Alexa fluor 
488-conjugated goat anti-rabbit IgG (Molecular Probes) 
antibody or Alexa fluor 594-conjugated goat anti-mouse 
IgG (Molecular Probes). The cell nuclei were stained with 
DAPI. Fluorescent imaging was performed utilizing Leica 
SP5 fluorescence microscopy driven by LAS software 
(Leica Microsystems). 
Flow cytometry
After the addition of drugs at indicated time points, 
cells were collected and washed with ice cold PBS and 
fixed with ice cold 70% ethanol. Cells were treated with 
500 µg/ml of RNase A (Sigma) and subsequently stained 
with 50 µg/ml of propidium iodide (PI, Sigma) for 15 
minutes at 37°C. The populations of cells stained by 
PI were then analysed by FACS calibre flow cytometer 
(Beckton Dickinson).
Clonogenic assay
C2 and PTEN shRNA ells were treated with variable 
concentrations of SN38 (notably 0uM, 0.5nM, 1nM, 
2.5nM, 5nM, 7.5nM) for 24 hrs. Then cells were plated as 
50 cells per well in 6 well plate in normal media. After 12 
days when colonies were apparent, cells were fixed with 
6% glutaraldehyde and 0.5% crystal violet for 15 min. 
Then cells were washed in a tub of water. The colonies 
per well were counted. 
Statistical analysis
In the siRNA library screening, we calculated the 
Z-score using the formula (mean gene-mean control)/sd 
(control). Bonferonni corrections were used to determine 
the significance threshold (p = 0.0025). For other statistical 
analysis, a student t-test with one-sided analysis was used. 
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